Piper Sandler analyst David Amsellem initiated coverage of Karuna Therapeutics with an Overweight rating and $285 price target. The analyst believes Karuna’s KarXT is poised to emerge as "valued and versatile" option in a schizophrenia space that has been "starved for mechanistically unique options." Peak U.S. sales approaching $3B are realistic, Amsellem tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KRTX: